| Bioactivity | LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1]. |
| Invitro | In human retinal microvascular endothelial cells (RMVECs), treatment with LCKLSL (0-2 mg) inhibits the generation of plasmin and suppresses the VEGF-induced activity of tPA under hypoxic conditions[1]. |
| Name | LCKLSL |
| CAS | 533902-29-3 |
| Sequence | Leu-Cys-Lys-Leu-Ser-Leu |
| Shortening | LCKLSL |
| Formula | C30H57N7O8S |
| Molar Mass | 675.88 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
LCKLSL
CAS: 533902-29-3 F: C30H57N7O8S W: 675.88
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.